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Registration: PROSPERO review registration (CRD42016047185) on 20 September 2016 
prior to review start (Shorter et al., 2016a). This work is part of and informs the Outcome 
Reporting in Brief Intervention Trials: Alcohol project (ORBITAL) which aims to create a 
core outcome set or minimum data standard for alcohol brief intervention trials. This 
ORBITAL project arose from collaborations in the International Network on Brief 
Interventions for Alcohol and Other Drugs [INEBRIA] Research Measurement 
Standardization Special Interest Group. This was registered at the start of the project at the 
COMET Initiative (Shorter et al., 2016b) and the protocol has been published (Shorter et al., 
2017).   
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Abstract 
Objective: To characterize recent alcohol brief intervention (ABI) efficacy and effectiveness 
trials; summarize outcomes; and show how variability in outcomes and reporting 
compromises the evidence base. 
 
Method: A systematic review and narrative synthesis of articles from 10 databases were 
undertaken (Jan 2000-Nov 2017); study selection represented recent, readily available 
publications. Alcohol brief intervention definitions were informed by National Institute of 
Clinical Excellence (NICE) Public Health Guideline 24: Alcohol use disorders: prevention. 
The review was conducted using Centre for Reviews and Dissemination (CRD) guidance and 
pre-registered on PROSPERO (CRD42016047185). Seven a priori specified domains were 
used to classify outcomes: biomarkers, alcohol related outcomes, economic factors/resource 
use, health measures, life impact, intervention factors, and psychological/behavioral factors. 
 
Results: The search identified 405 trials from 401 eligible papers. In 405 trials, 2641 separate 
outcomes were measured in approximately 1560 different ways. The most common outcomes 
used were number of drinks consumed in a week and frequency of heavy episodic drinking. 
Biomarkers were least frequently used. The most common primary outcome was weekly 
drinks. By trial type, the most frequent outcome in efficacy and effectiveness trials was 
frequency of heavy drinking. 
 
Conclusions: Consumption outcomes predominated; however, no single outcome was found 
in all trials. This comprehensive outcome map for ABI effectiveness and efficacy trials can 
aid decision making in future trials. There was diversity of instruments, time points, and 
outcome descriptions in methods and results sections. Compliance with reporting guidance 
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would support data synthesis and improve trial quality. This review establishes need for a 
core outcome set/minimum data standard (COS) and supports the Outcome Reporting in 
Brief Interventions: Alcohol initiative (ORBITAL) to improve standards in the ABI field 
through a COS for effectiveness and efficacy randomized trials. 
 
Keywords: Alcohol drinking; alcohol brief interventions, randomized controlled trials, 
outcome assessment, core outcome set, systematic review 
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Introduction 
Alcohol brief interventions (ABIs) are key strategies to address problematic alcohol use 
worldwide (Coffield et al., 2001; National Institute for Health and Clinical Excellence, 2010; 
US Preventive Services Task Force, 2004; World Health Organisation [WHO], 2016). 
Numerous systematic reviews (Ballesteros et al., 2003; Ballesteros et al., 2004a; Ballesteros 
et al., 2004b; Beich et al., 2003; Bertholet et al., 2005; Kaner et al., 2018; O'Donnell et al., 
2014) suggest ABIs in primary health care are effective, but these reviews report substantial 
outcome heterogeneity, limiting the strength of conclusions. Commentators have urged 
caution in making broad clinical practice recommendations as a result (Bernstein et al., 2009; 
Bernstein et al., 2010; Field et al., 2010; Heather, 2016; McCambridge & Saitz, 2017; Saitz et 
al., 2006; Saitz, 2010). 
 
An avoidable problem is the diversity in definition and measurement of outcomes used. This 
reduces the ability to meaningfully synthesize available information. For example, in a recent 
and comprehensive review (Kaner et al., 2018), authors excluded 22 of 69 otherwise eligible 
studies due to outcome reporting issues. Differing outcomes across studies weakens meta-
analyses of the efficacy and effectiveness of ABIs and contributes to research waste as not all 
articles can be used for the evidence base (Glasziou, 2014). Given the number of reviews 
mentioning outcome heterogeneity across all populations in which ABIs are now employed, 
it is no longer appropriate to dismiss this heterogeneity as a limitation, when it can and 
should be addressed. 
 
To address outcome heterogeneity in ABI trials, future ABI studies should use a coherent, 
consistent set of outcomes, known as a core outcome set (COS). A COS is a feature of a 
mature research base, and many healthcare areas have developed, or are developing, COS to 
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support advances in their field (COMET Initiative, 2017). A COS reduces selective and 
inconsistent reporting in research trials, improves the quality of treatment guidance for a 
condition, and increases the number of studies synthesized in systematic reviews. Both the 
Consolidated Standards of Reporting Trials (CONSORT) (Moher et al., 2010) and the 
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statements 
recommend COS use, and a formal process for COS development has been established by the 
Core Outcome Measures in Effectiveness Trials (COMET) Initiative (Williamson et al., 
2017; Williamson et al., 2012). A COS is a minimum reporting standard, and does not restrict 
the measurement of additional outcomes. A comprehensive map of outcomes can support 
decision making on other outcomes to be measured alongside the COS; reducing a potential 
source of conflict in trial planning (Daykin et al., 2016; Daykin et al., 2017). 
 
Recognizing the benefits an ABI COS could provide, the International Network on Brief 
Interventions for Alcohol and Other Drugs (INEBRIA) Research Measurement 
Standardization-Special Interest Group (IRMS-SIG) established the Outcome Reporting in 
Brief Intervention Trials: Alcohol (ORBITAL) project to derive a COS using COMET 
guidelines. This systematic review is a component of ABI COS development and follows the 
ORBITAL protocol (Shorter et al., 2017). Although numerous systematic reviews on ABI 
have been conducted, most have aimed to establish efficacy, effectiveness, and/or cost-
effectiveness, and their included studies meet a restrictive set of eligibility criteria, including 
their pre-specified outcome of interest. No study to date has compiled all outcomes used 
across ABI studies. This paper fills this gap through a definitive catalogue of outcomes used 
in recent ABI trial literature. Such a catalogue is needed to a) map outcomes used to 
demonstrate efficacy and effectiveness in peer-reviewed, published ABI trials, b) demonstrate 
the variability in outcome type and measurement, c) highlight methodological issues in the 
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ABI field around outcomes and reporting, d) inform COS development, including identifying 
outcomes for a Delphi prioritization exercise (see Shorter et al., In Press), and e) support ABI 
trial protocol decision making on outcomes by trial area.  
Methods 
A review protocol was registered in advance on PROSPERO (CRD42016047185) (Shorter, et 
al., 2016a). Medline [OVID], EMBASE, PsycINFO [OVID], Health Management 
Information Consortium [HMIC], Cumulative Index to Nursing and Allied Health Literature 
[CINAHL], Allied and Complementary Medicine Database [AMED], Cochrane Library, 
ERIC [EBSCO], Web of Science, Google Scholar, Clinicaltrials.gov, and WHO International 
Clinical Trials Registry Platform [ICTRP] databases were searched to identify trials 
published between January 2000-November 2017 in peer-reviewed journals. This date range 
provided balance between capturing an extensive evidence base and reflecting the current 
state of ABI research. We focus on peer-reviewed publications as readily available in the 
public domain and reflect the work of the COS target audience (policy, practice, and 
research). Core search concepts related to three domains: alcohol use; brief interventions; and 
randomized trials. Terms were coupled with relevant MeSH/thesaurus terms, truncated as 
appropriate, and variant spellings were used to identify useful records (Supplementary 
Material A contains the OVID search which was adapted for other databases). 
 
Eligible studies were individual or cluster randomized trials focused on efficacy or 
effectiveness of ABIs designed to reduce alcohol consumption published in peer-reviewed 
journals. Trials that did not analyze outcomes by randomized arm were excluded (e.g. 
subsample analysis only). Papers with the same trial registration number were included if 
they assessed different outcomes in each. Specific search parameters are described below.  
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Population: Current drinkers (at least one drink in the past year) who were aged 16 years or 
above. Trials of drinkers aged 15 years or below were excluded, as were trials including 
individuals seeking treatment for alcohol problems, following related UK NICE guidance 
(National Institute for Health and Clinical Excellence, 2010).  
 
Intervention: ABIs were defined as those suitable for drinkers not seeking treatment for an 
alcohol problem but who are identified by screening as having, or being at risk of, problems 
from their alcohol use (National Institute for Health and Clinical Excellence, 2010). This 
definition covers brief advice and extended brief interventions, delivered once or more 
frequently. An ABI should assess an individual’s alcohol use and provide feedback on their 
alcohol assessment. Trials including a multicomponent intervention arm or where one or 
more intervention components addressed non-alcohol related health behaviors (e.g., smoking 
cessation) were included if alcohol intervention components and outcomes could be clearly 
distinguished.  
 
Comparator: Comparators could be any active or control intervention.  
 
Outcomes: All outcomes analyzed by randomized arm were extracted including detail of how 
the outcome was defined and measured if possible. This was used to estimate the variability 
in outcome measurement, i.e. to what extent an outcome in one paper was exactly the same as 
in another paper (what the outcome represents, how it was measured and scored, and time 
period referred to). Other extracted information included: number and nature of sample 
randomized (sex, age, and population), trial details, including region, number of trial arms, 
trial arm composition, trial type (efficacy/effectiveness/not reported), and details of follow up 
timing. These were summarized either as number (%) or mean (SD) of trials included with 
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indication of missing data in the total number. Broad indicators of trial reporting quality were 
included: stating ‘trial’ in the title or including a participant flow chart in line with early 
CONSORT guidance (Begg et al., 1996). Where study information was not provided this was 
stated. Effectiveness and efficacy ABI reviews often contact authors for missing data, we did 
not do so as our aim was to highlight where reporting falls short to improve standards in the 
field like other, similar high quality methodological reviews (Harman et al., 2017; Riddle et 
al., 2008; Thornley & Adams, 1998).  
 
A taxonomy was created to map outcomes under seven domains: alcohol related outcomes; 
biomarkers; health measures; economic factors/social impacts; psychological/behavioral 
factors; life impact; and intervention factors. This was influenced by a range of sources. The 
first draft was informed by a presentation at the COMET V meeting in Amsterdam (attended 
by GWS in September 2016), since published in Dodd et al. (2018). However, given the ABI 
topic area is not directly concerned with physical pathology, many clinical factors in this 
taxonomy were irrelevant (e.g. musculoskeletal outcomes), whereas other outcomes were not 
specific enough (e.g. emotional functioning/wellbeing). Other sources included the Outcome 
Measurement Sets for Clinical Trials [OMERACT] filter (Boers et al., 2014); this was helpful 
to derive core areas such as death, life impact, resource use, or pathophysiological 
manifestations, but was too broad to capture outcomes relevant to ABIs. The Patient-
Reported Outcomes Measurement Information System [PROMIS] (Cella et al., 2007) 
provided elaboration to describe some outcomes in ABI trials (anxiety, depression, or sleep 
disturbance) but there were classification limitations, and some outcomes (e.g. PROMIS 
alcohol use questionnaire) were absent from ABI papers. We drew upon health economic 
reviews to inform the economic outcomes domain (Barbosa et al., 2015; Barbosa et al., 2010; 
Bray et al., 2011). Outcome data extracted from ABI trials were used to refine the taxonomy 
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further. GWS created the taxonomy, this was then refined by others (NH, DNB, JWB, AHB, 
CB, and ELG). 
 
Search results were downloaded to EndNote version X7 and de-duplicated. GWS screened all 
titles and abstracts of papers and excluded those that did not meet the inclusion criteria. DNB 
checked 28% of these for accuracy; discrepancies were resolved by discussion. All full text 
versions of potentially eligible papers were reviewed by GWS, and all double-screened by 
one of ELG, DNB, JWB, AJOD, AHB, and AH; discrepancies were resolved by discussion. 
Extraction forms were piloted by GWS and KJS. All data were extracted by GWS, and all 
extracted data cross-checked for accuracy by at least one of ELG, DNB, SJS, KJS, JWB, 
AJOD and AHB. Data were presented from all trials, and split by population (‘primary care’, 
‘emergency department’, ‘University/College’, ‘general population’ (i.e. a general adult 
sample not selected as having specific characteristics), ‘other healthcare’, and ‘other’ 
populations (including workplaces or job related populations (n=14), veteran populations 
(n=19), community sample of persons with an intellectual disability (n=1), homeless 
population (n=1), criminal justice populations (n=14), licensed premises (n=1), sports clubs 
(n=1), and young people aged 16+ years (n=6)). A PRISMA checklist is in Supplementary 
Material B. 
Results 
Searches identified 33,134 papers after de-duplication to be screened by title and abstract for 
eligibility. Exclusion at title and abstract stage reflected unambiguous violation of the above 
PICO (population, intervention, comparator, outcomes) on the basis of topic area (i.e. not 
alcohol) or a known alcohol treatment sample (such as Project MATCH). Any unclear 
matches were referred to full text assessment for closer inspection; 1,612 papers were 
retrieved for full text evaluation against PICO criteria, and 401 were deemed eligible (Figure 
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1). The 401 included papers covered 405 individual trials (some papers reported two trials), 
representing 182,272 randomized participants in total (see Supplementary Material C for 
included papers) 
<<<Figure 1>>> 
The mean trial size was 450 individuals (range=12-7,935). Typically, higher numbers were 
randomized in ‘primary care’, ‘emergency department’, and ‘general population’ samples 
compared to the remaining populations (Table 1). There were slightly more males than 
females on average (mean % male=56.2; SD=28.1); highest in the ‘other’ population. Most 
trials were conducted in North America (60.7%); this was particularly evident in the 
‘University/College’ population with 81.1% of trials from this region. Two-arm trial designs 
predominated, with trials in the ‘emergency department’ and ‘University/College’ 
populations more likely to have more than two arms. Around 83% of trials had a non-ABI 
control group. ‘Other’ populations were most likely to have a non-ABI control (91.2%) and 
‘General population’ were least likely (75.0%). More trials were declared by their authors as 
efficacy trials (52.8%) compared to effectiveness trials (42.0%). Twenty-one trials did not 
state their type. Only ‘University/College’ populations had more effectiveness trials (56.1%) 
than efficacy trials (40.2%). 
 
<<<Table 1>>> 
 
Just over half the trials indicated they were a trial in the paper’s title (52.1%); 63.7% included 
a flow chart of participants through the trial. ‘University/College’ populations were least 
likely to report these elements, with ‘general population’ trials more likely to state they were 
a trial (67.2%), and ‘other healthcare’ populations more likely to include a flow chart 
(78.2%). Broadly similar percentages had two or three data collection waves (42% and 38% 
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respectively). Longer-term follow-up of two or more years was more likely in ‘primary care’ 
(n=7; 14%). Short-term follow-up was more likely in ‘University/College’ samples. Overall, 
trialists most often selected three-month intervals for follow-up (e.g. three or six months). 
Over time, there was a general increase in the number of ABI trials published per year. The 
largest number were published in 2014. The number of trials per year is given in Figure 2. 
<<<Figure 2>>> 
Outcomes 
Overall, 2,641 outcomes were extracted from 405 trials. Only 285 trials stated if their 
outcomes were primary or secondary. The mean number of outcomes per trial was 6.5 
(ranging from 1-56); highest in ‘primary care’, and lowest in ‘University/College’ samples. 
On average, there were two primary, and four secondary outcomes reported in the included 
trials. Most trials had at least one alcohol related outcome measure. The highest percentage of 
trials with at least one health outcome was in the ‘primary care’ or ‘other healthcare’ 
population, least likely in the ‘University/College’ population. Economic factors or social 
impacts were most likely in the ‘primary care’ or ‘emergency department’ population. 
Psychological factors were found in around 28% of trials, most commonly in ‘other 
healthcare’ populations. Life impact outcomes were present in 56 trials. Less than 10% of 
trials looked at intervention factors and ‘University/College’ samples were more likely to 
have one outcome of this type. Biomarkers were infrequently used: only 13 trials had 
measured at least one biomarker; more likely in ‘primary care’ or ‘other’ populations. 
 
Alcohol related outcomes 
Alcohol related outcomes include those connected to the amount or pattern of alcohol 
consumption, those related to the comorbid use of other substances and those reflecting 
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substance use disorder symptomology. As such, it is broader than just alcohol consumption 
measures but we have retained the term “alcohol related outcomes” for ease of exposition and 
to maintain consistency with our protocol (Shorter et al., 2017) and Delphi study (Shorter et 
al., In Press). In the 405 trials, there were 1,456 alcohol related outcomes measured in 744 
different ways (Table 2). The most commonly reported alcohol related outcome variables 
were frequency of heavy drinking (n=213), weekly drinks (n=205), alcohol related problems 
or consequences (n-190), typical quantity (n=137), typical frequency (n=117), and hazardous 
or harmful drinking (n=111). Many of the infrequently-measured outcomes were also the 
most diversely measured. An exception included ‘at risk drinking’ (which measures risk 
derived from publicly-available recommendations such as weekly or single episode limits). 
By population, ‘primary care’ trials were most likely to report weekly drinks, frequency of 
heavy drinking, and at-risk drinking. This was somewhat similar to the ‘general population’, 
‘emergency department’ and ‘University/College’ populations, which often measured weekly 
drinks, frequency of heavy drinking, and alcohol- related problems or consequences. The 
majority of trials that measured blood alcohol concentration were in the ‘University/College’ 
population. ‘Other healthcare’ populations often measured typical and heavy drinking 
frequencies, and hazardous and harmful drinking. Frequency of heavy drinking was the most 
commonly reported outcome in both efficacy and effectiveness trials, with the number of 
drinks consumed in a week the most frequent primary outcome. 
<<<Table 2>>> 
Other outcomes 
In total, 32 biomarker outcomes were reported across the 405 trials (Table 3). Of these, the 
most commonly reported was gamma-glutamyltransferase (GGT). Biomarkers were only 
found in ‘primary care’, ‘other healthcare’, and ‘other’ populations. The most frequent 
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biomarker in efficacy trials was GGT, in effectiveness trials it was Carbohydrate-deficient 
transferrin (CDT). GGT and CDT tied as the most common primary outcome.  
 
In the economic factors/social impacts domain, the most commonly reported outcomes were 
driving related offences and hospitalizations. This domain includes some overlap with 
measures of alcohol related consequences in the alcohol related outcome domain, but 
measures in this domain are intended to assess social costs and impacts, not to assess the 
possibility of a diagnosable alcohol disorder. In ‘primary care’, the most commonly reported 
economic factors/social impacts outcomes were driving-related offences, hospitalizations, 
other criminal justice use, or other healthcare use. For ABI trials set in the ‘emergency 
department’, the most common were seeking alcohol treatment, driving-related offences, and 
emergency healthcare use. In ‘other healthcare’ populations, the most commonly-assessed 
economic variable was that of provider intervention costs. In ‘other’ populations, given the 
composition of this group, other criminal justice use was most common. Economic 
factors/social impacts measures were not commonly reported by ‘general population’ or 
‘University/College’ ABI trials. The intervention cost to the provider was the most common 
economic factors/social impacts measure for efficacy trials. Driving related offences was the 
most common measure in effectiveness trials, and the most reported primary outcome. 
 
Health outcomes most commonly reported were alcohol-exposed pregnancy factors, 
psychological health measures, sexual violence or coercion, and severity of depression 
symptoms. In ‘primary care’, cardiac factors, psychological health, and physical health were 
most commonly reported. In ‘general population’ samples, alcohol-exposed pregnancy 
factors or severity of depression were more commonly reported. Sleep disruption was only 
measured in ‘University/College’ ABI trials. ‘Other healthcare’ populations most commonly 
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reported alcohol-exposed pregnancy factors. The most frequent efficacy outcome in this 
domain was psychological health; the most common outcome in effectiveness trials was 
alcohol-exposed pregnancy factors. The most commonly reported outcome from the 
intervention factors domain was intervention satisfaction; true for both effectiveness and 
efficacy trials. ABI trials in ‘University/College’ and ‘general population’ samples were more 
likely to ask participants about this outcome. 
 
In the domain of psychological and behavioral factors, the most commonly reported 
outcomes across all trials were drinking refusal self-efficacy, alcohol outcome expectancies, 
risky behaviors, and readiness to change. ABI trials in the ‘primary care’ and ‘emergency 
department’ populations were least likely to measure these outcomes. By contrast, 
‘University/College’ samples were particularly likely to measure the perception of others’ 
drinking, for example, the typical quantity drunk by a student at their institution. For ‘general 
population’ samples, drinking refusal self-efficacy and readiness to change were most 
common. In ‘other healthcare’ populations, risky behaviors were the most commonly 
reported; these include aspects such as sex without effective contraception. Finally, in ‘other’ 
populations, anger and aggression, drinking refusal self-efficacy, other psychological factors, 
and readiness to change were the most commonly reported outcomes. The most frequent 
measure in efficacy trials was readiness to change; for effectiveness trials it was perception of 
others’ drinking. The most common primary outcome for both was engagement in risky 
behaviors. Life impact measures were most commonly role functioning or relationship factors 
or quality of life. The former was most common in effectiveness trials (and as a primary 
outcome), the latter the most common for efficacy trials. 
<<<Table 3>>> 
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Discussion 
This review is the first to go beyond stating outcome heterogeneity as a weakness in ABI 
systematic reviews; it quantifies the heterogeneity and inconsistency in outcomes reported in 
effectiveness and efficacy trials of ABIs. Overall, there were 2,641 outcomes measured in 
approximately 1,560 different ways, truly a “Tower of Babel”. The estimated 1,560 different 
ways outcomes were measured may be a conservative guess of the true variability given the 
lack of precision on how outcomes were measured. The variation in the outcomes used and 
reported across ABI trials reflects similar reviews conducted in different research areas 
(Harman et al., 2017). For the ABI field, the substantial heterogeneity represents an important 
challenge. Meta-analyses will continue to be compromised as they cannot draw on all 
evidence to decide whether ABIs work as intended. Just over half (53%) measured the most 
common consumption measure frequency of heavy drinking; this creates a considerable 
conflict between the drive for inclusion of all studies meeting criteria in high quality 
systematic reviews, and the ability to include all studies in the meta-analysis. 
 
Determining efficacy or effectiveness depends on outcomes measured, and therefore all ABI 
trial papers should contain sufficient detail on outcome measurement. One way this may 
affect meta-analyses is through the combination of an outcome (e.g. weekly drinks) which 
hides considerable variability. For example, “weekly drinks” may refer to an average week, a 
typical week, or the last week. It may refer to a typical week in the past month, 28 days, 90 
days, six months, or since last measurement. The definition of drink may be specified or left 
to the respondent. Weekly drinks may be reported directly or calculated based on other 
information in a range of different questionnaires. We can calculate some differences to be 
equivalent, but some measure genuine differences and their combination compromises the 
validity of estimates. At a minimum trials should report a) what the outcome is, b) the 
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question or questionnaire used to measure and how this is used (e.g. scale score, or the binary 
above and below a cut-off point), c) measure of aggregation such as mean value or mean 
individual difference, and d) time point (e.g. 1, 4, and 8 weeks post intervention).  
 
Some trials did not specify whether their outcomes were primary or secondary outcomes. 
This could be because the trial was a pilot study and specification may not be required 
(Eldridge et al., 2016), or it might be stated in a trial registry. However, excluding this from 
reporting is problematic (Begg, et al., 1996; Moher, et al., 2010). In addition, although one 
might expect trials to have only one primary outcome, we found, of those who specified, the 
average was two primary outcomes. This was an under-estimate of the average because some 
papers only reported secondary outcomes; their primary outcome(s) were in other papers with 
the same trial registration number. The correct interpretation of secondary outcomes is 
‘through’ the primary analysis on the premise that, if the primary outcome is positive, then 
secondary outcomes can help to understand how the ABI worked. The secondary designation 
may also be useful for outcomes more distal on the causal pathway that reduced drinking 
would be expected to change. If the primary outcome is neutral, the secondary outcomes are 
hypothesis-generating. If the primary outcome is ‘negative’, the secondary outcomes provide 
insight into how the treatment caused harm (Freemantle, 2001). If change is shown in some 
primary outcomes but not others, interpretation can become difficult and it may be a 
challenge to state the ABI brought about change. To improve the aggregation of trials into the 
evidence base, outcomes (from a COS or otherwise) should be detailed, identified as primary 
or secondary with a clear statistical analysis plan, well reported in results sections which 
include point estimates and variability around estimates, and follow reporting guidance.  
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Alcohol related outcomes, particularly consumption outcomes, were the predominant 
outcomes measured in ABI trials. Although some have called for an increase in biomarkers in 
ABI trials (Kypri, 2007) this call has not been heeded; most outcomes were self-reported. 
ABI effectiveness or efficacy meta-analyses rely on the outcomes reported without validating 
them against objective measures (Moyer et al., 2002), exacerbating the problem of outcome 
heterogeneity in ABI trials. Our review provides the first systematic and quantifiable 
evidence to support previous calls for standard definitions of ABI outcomes to compare 
across studies (Bernstein et al., 2010).  
 
Despite efforts to identify literature from across the globe, most trials were from North 
American or European countries. This may reflect the predominance of publishing or funding 
opportunities available to those researchers, the high levels of hazardous and harmful use of 
alcohol in these countries (Rehm et al., 2009), or be a consequence of the pre-specified 
databases searched. We attempted to minimize English language bias and improve the quality 
of the review by including studies reported in languages other than English (Moher et al., 
2003).The searching was largely conducted in English, and our ability to extract data from 
articles in languages other than English was limited, as shown in the CONSORT flowchart 
(Figure 1). Although focusing on peer-reviewed literature may have also limited the number 
of non-English articles included, it is in keeping with our intention to focus on those articles 
that are likely to be most accessible and influential for many decision makers. Our searches 
of the grey literature, which constitute a separate part of our PROSPERO-registered 
systematic review not reported here, will be one opportunity to explore how improving access 
to a wider range of literature from low-resource settings or from reports in languages other 
than English, may influence the evidence base. This limitation is likely to have shown 
additional heterogeneity in findings, as the number of valid trials increased. 
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There was also a predominance of efficacy trials in the included studies, and attention should 
turn towards effectiveness trials within the different populations. Efficacious interventions 
may not be effective in routine practice (McCambridge & Saitz, 2017). Some trials did not 
specify their trial approach as either efficacy or effectiveness; although this may be a 
consequence of challenges of specification across the efficacy to effectiveness continuum 
(Heather, 2014). Short-term follow up was common, as reported by other systematic reviews 
(Moyer, et al., 2002). This is perhaps expected given effect sizes tend to be larger at early 
follow up, and there are concerns about the longitudinal effects of ABI (Donoghue et al., 
2014). The predominant follow-up interval was around three months between data collection 
points. With around 20% of studies with four or more follow-up points, there is a balance 
between minimizing loss to follow-up, timely collection of only important information, and 
respondent burden (Lin et al., 2012).  
 
By synthesizing outcome selection, this review offers the opportunity to consider outcome 
choice and the implications for the ABI field; other healthcare areas have noted the 
importance of design in attrition (Kilburn et al., 2014). Others have considered respondent 
burden (Cunningham et al., 1999; Kypri, 2007); as the number of outcomes reported was 56 
in one trial, this may need careful consideration. Decision making around which outcomes to 
use for particular trials can be assisted by this outcome map, broken down by research area, 
effectiveness/efficacy, and primary/secondary/other outcomes. The structure of this outcome 
map was the process of discussion between co-authors, and we recognize that other structures 
of categorization may also exist.  
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This review highlights the importance of a COS for efficacy or effectiveness ABI randomized 
trials . This review will contribute to the efforts to establish a COS using high quality, 
established methodologies (Williamson, et al., 2017), which will improve and standardize 
reporting in the ABI field. This review also informs a preliminary list of outcomes for a 
related e-Delphi prioritization exercise (Shorter et al., In Press) and for discussion at the 
consensus meeting as outlined in the ORBITAL protocol (Shorter et al., 2017). We aimed to 
better understand how the extent of variability and reporting of outcomes compromises the 
evidence base and have conclusively shown this variability is considerable, and reporting is 
incomplete. The ability of users of ABI research to compare and understand findings is 
restricted because we do not know what exactly was measured and how, nor can we 
confidently compare seemingly alike outcomes. We did not seek to improve the completeness 
of the data by contacting the original authors, but used the incompleteness (contrary to usual 
systematic review practice) as a tool to highlight shortcomings in the field. We must improve 
issues of reporting and methodological quality to advance the field; the ABI evidence base 
cannot move from middle age to more established without it (Babor et al., 2007). 
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Figure 1: PRISMA Flow Diagram for the systematic review of outcomes in efficacy and 
effectiveness trials of alcohol brief interventions 
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Table 1: Features of readily available peer-reviewed randomized trials of alcohol brief interventions (published 01/01/00-31/10/17) 
  Overall 
N=405 
Primary care 
N=50 
Emergency  
Department 
N=47 
University/ 
College N=132 
General 
population 
N=64 
Other 
healthcare  
N=55 
Other* 
N=57 
Trial size Mean (SD)  
Range of those randomized 
450.1 (730.1) 
12-7935 
540.0 (967.6) 
29-6897 
628.3 (692.9) 
45-4476 
414.1 (662.3)  
18-5227 
549.5 (1074.3) 
29-7935 
277.3 (246.5) 
40-975 
362.4 (404.7) 
12-1449 
Sex of those 
randomized 
Mean % (SD) - males 56.2 (28.1) 65.4 (27.0) 67.6 (17.2) 45.9 (17.6) 56.1 (28.4) 46.4 (39.1) 76.1 (27.3) 
Not reported/split by arm 65 9 17 15 6 8 10 
Age of those 
Randomized 
Mean age in years (SD) 31.6 (13.3) 48.2 (14.8) 30.9 (6.5) 20.4 (2.3) 39.1 (10.4) 37.3 (10.5) 34.1 (14.1) 
Not reported/split by arm/ grouped age 137 23 24 36 19 16 19 
Trial region 
 
N (%) North America  246 (60.7%) 23 (46.0%) 32 (68.1%) 107(81.1%) 32 (50.0%) 22 (40.0%) 30 (52.6%) 
N (%) Australia & NZ 20 (4.9%) 1 (2.0%) 1 (2.1%) 6 (4.5%) 4 (6.3%) 3 (5.5%) 5 (8.8%) 
N (%) Europe 110 (27.2%) 18 (36.0%) 13 (27.7%) 16 (12.1%) 25 (39.1%) 19 (34.5%) 19 (33.3%) 
N (%) South America 4 (1.0%) 0 1 (2.1%) 2 (1.5%) 0 0 1 (1.8%) 
N (%) Africa  10 (2.5%) 4 (8.0%) 0 1 (0.8%) 0 5 (9.1%) 0 
N (%) Asia 15 (3.7%) 4 (8.0%) 0 0 3 (4.7%) 6 (10.9%) 2 (3.5%) 
# Trial arms N (%) with 2 arms 293 (72.3%) 39 (78.0%) 31 (66.0%) 85 (64.4%) 46 (71.9%) 45 (81.8%) 47 (82.5%) 
N (%) with 3 arms 82 (20.2%) 9 (18.0%) 14 (29.8%) 28 (21.2%) 11 (17.2%) 10 (18.2%) 10 (17.5%) 
N (%) with 4+ arms 30 (7.5%) 2 (4.0%) 2 (4.3%) 19 (14.4%) 7 (10.9%) 0 0 
Trial arm 
composition 
N (%) with 1+ arms not ABI 335 (82.7%) 39 (78.0%) 40 (85.1%) 108(81.8%) 48 (75.0%) 48 (87.3%) 52 (91.2%) 
N (%) with 1 ABI 249 (61.5%) 28 (56.0%) 31 (66.0%) 68 (51.5%) 36 (56.3%) 43 (78.2%) 43 (75.4%) 
N (%) with 2+ ABI 156 (38.5%) 22 (44.0%) 16 (34.0%) 64 (48.5%) 28 (43.7%) 12 (21.8%) 14 (24.6%) 
Trial type N (%) Efficacy 214 (52.8%) 34 (68.0%) 31 (66.0%) 53 (40.2%) 31 (48.4%) 33 (60.0%) 32 (56.1%) 
N (%) Effectiveness 170 (42.0%) 16 (32.0%) 15 (31.9%) 74 (56.1%) 27 (42.2%) 17 (30.9%) 21 (36.8%) 
N (%) Unclear 21 (5.2%) 0 1 (2.1%) 5 (3.8%) 6 (9.4%) 5 (9.1%) 4 (7.0%) 
Reporting 
quality 
N (%) Included “trial” in title 211 (52.1%) 22 (44.0) 23 (48.9%) 53 (40.2%) 43 (67.2%) 33 (60.0%) 37 (64.9%) 
N (%) Included flowchart 258 (63.7%) 35 (70.0) 35 (74.5%) 63 (47.7%) 44 (68.8%) 43 (78.2%) 38 (66.7%) 
# of data 
collection 
waves 
N (%) with 2 waves 168 (41.8%) 20 (40.8%) 16 (34.0%) 63 (48.1%) 27 (42.2%) 19 (34.5%) 23 (41.1%) 
N (%) with 3 waves 153 (38.1%) 18 (36.7%) 24 (51.1%) 44 (33.6%) 24 (37.5%) 29 (52.7%) 14 (25.0%) 
N (%) with 4+ waves 81 (20.1%) 11 (22.4%) 7 (14.9%) 24 (18.3%) 13 (20.3%) 7 (12.8%) 19 (33.9%) 
Follow up 
wave timing 
N (%) 0 – 2 weeks 10 (2.5%) 0 0 8 (6.1%) 0 1 (1.8%) 1 (1.8%) 
N (%) >2w – 1 month 91 (22.5%) 5 (10.0%)  2 (4.3%) 54 (40.9%) 13 (20.1%) 8 (14.5%) 9 (15.8%) 
N (%) >1m - 2m 56 (13.8%) 3 (6.0%) 0 27 (20.5%) 9 (14.1%) 7 (12.7%) 10 (17.5%) 
N (%) >2m - 3m 168 (41.5%) 19 (38.0%) 25 (53.2%) 44 (33.3%) 30 (46.9%) 20 (36.4%) 30 (52.6%) 
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N (%) >3m - 4m 14 (3.5%) 1 (2.0%) 1 (2.1%) 5 (3.8%) 1 (1.6%) 2 (3.6%) 4 (7.0%) 
N (%) >4m - 6m 202 (49.9%) 30 (60.0%) 23 (48.9%) 51 (38.6%) 36 (56.3%) 33 (60.0%) 29 (50.9%) 
N (%) >6m – 9m 32 (7.9%) 3 (6.0%) 3 (6.4%) 10 (7.6%) 3 (4.7%) 8 (14.5%) 5 (8.8%) 
N (%) >9m – 12m 120 (29.6%) 24 (48.0%) 30 (63.8%) 20 (15.2%) 14 (21.9%) 20 (36.4%) 12 (21.1%) 
N (%) >12m – 18m 14 (3.5%) 0 2 (4.3%) 2 (1.5%) 0 4 (7.3%) 6 (10.5%) 
N (%) >18m – 24m 17 (4.2%) 6 (12.0%) 0 3 (2.3%) 4 (6.3%) 3 (5.5%) 1 (1.8%) 
N (%) >24m 13 (1.7%) 7 (14.0%) 1 (2.1%) 3 (2.3%) 2 (3.1%) 0 0 
# and type of 
outcomes 
Mean (SD) # primary outcomes (n=285) 2.4 (2.0) 2.7 (3.0) 2.3 (1.3) 2.9 (2.4) 2.3 (1.3) 1.9 (1.3) 2.0 (1.6) 
Mean (SD) # secondary (n=285) 4.1 (6.0) 5.3 (6.8) 5.1 (6.4) 2.6 (3.6) 4.3 (8.7) 4.5 (4.1) 3.9 (5.0) 
Mean (SD) # not specified (n=120) 6.4 (4.5) 11.2 (8.8) 5.9 (2.8) 6.0 (4.1) 4.8 (1.7) 5.6 (4.1) 8.1 (5.6) 
Mean (SD) # outcomes per trial (n=405) 6.5 (5.8) 8.4 (7.3) 7.0 (5.8) 5.7 (3.9) 6.3 (8.0) 6.1 (4.1) 6.5 (5.0) 
Trials with at 
least one 
outcome from 
each of the 
following 
domains 
N (%) Alcohol related outcomes  388 (95.8%) 46 (92.0%) 45 (95.7%) 132 (100%) 63 (98.4%) 52 (94.5%) 50 (87.7%) 
N (%) Health 80 (19.8%) 16 (32.0%) 6 (12.8%) 10 (7.6%) 16 (25.0%) 19 (34.5%) 13 (22.8%) 
N (%) Economic factors/social impacts 87 (21.5%) 20 (40.0%) 23 (48.9%) 13 (9.8%) 5 (7.8%) 8 (14.5%) 18 (31.6%) 
N (%) Psychological/Behavioral Factors 114 (28.1%) 5 (10.0%) 11 (23.4%) 47 (35.6%) 14 (21.9%) 21 (38.2%) 16 (28.1%) 
N (%) Life Impact 57 (14.1%) 9 (18.0%) 8 (17.0%) 13 (9.8%) 11 (17.2%) 6 (10.9%) 10 (17.5%) 
N (%) Biomarkers 13 (3.2%) 6 (12.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (3.6%) 5 (8.8%) 
N (%) Intervention factors 38 (9.4%) 1 (2.0%) 3 (6.4%) 14 (10.6%) 14 (21.9%) 2 (3.6%) 4 (7.0%) 
* Other includes workplaces or job related populations (n=14), veteran populations (n=19), community sample of persons with an intellectual disability (n=1), 
homeless population (n=1), criminal justice populations (n=14), licensed premises (n=1), sports clubs (n=1), and young people (n=6). 
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Figure 2: Number of alcohol brief intervention papers published per year by population
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Table 2: Frequency and variability in reporting of alcohol related outcome variables overall and by population 
Outcome 
N times 
measured 
N ways 
measured 
Ratio of 
variability* 
Trial type*** 
Efficacy/ 
Effectiveness/ 
Not specified 
Outcome 
type**** 
Primary/ 
Secondary/ Not 
specified 
Primary 
care 
N=50 
Emergency 
Department 
N=47 
University/ 
College 
N=132 
General 
population 
N=63 
Other 
healthcare 
N=55 
Other 
N=57 
Frequency of heavy drinking 213 128 0.6 105/103/5 90/65/58 30 32 72 28 24 27 
Number of drinks consumed 
in a week 205 63 0.3 99/97/9 121/27/57 28 19 85 37 18 18 
Alcohol-related problems or 
consequences 190 73 0.4 84/98/8 47/62/81 9 28 97 26 8 22 
Typical quantity 137 63 0.5 81/49/7 53/38/46 17 16 45 22 19 18 
Typical frequency 117 73 0.6 58/50/9 47/25/45 5 12 43 16 22 19 
Hazardous or harmful 
drinking 111 27 0.2 83/20/8 34/49/28 21 15 14 15 25 21 
Blood alcohol concentration 76 39 0.5 41/33/2 28/18/30 0 1 62 7 3 3 
At risk drinking 72 63 0.9 48/23/1 34/29 9 8 9 15 6 5 
Largest number of drinks on 
occasion 57 36 0.6 22/31/4 23/17/17 0 10 30 9 5 3 
Days abstinent 44 28 0.6 28/13/3 16/22/6 8 4 0 7 14 11 
Combined consumption 
measure 42 17 0.4 21/9/2 20/9/13 5 3 10 12 7 5 
Tobacco 29 17 0.6 5/24/0 7/17/5 2 0 13 9 3 2 
Cannabis/marijuana use 26 19 0.7 7/18/1 6/13/7 2 2 16 2 2 2 
Number of drinks in a month 22 12 0.5 15/7/0 13/3/6 5 1 12 3 1 0 
Dependence symptomatology 19 10 0.5 14/4/1 3/10/6 3 5 3 3 3 2 
Polydrug use (alcohol +) 17 12 0.7 9/7/1 6/8/3 2 1 2 4 6 2 
Frequency of intoxication 15 9 0.6 9/5/1 1/4/10 2 3 6 0 2 2 
Other substance use 13 11 0.8 10/3/0 2/7/4 5 0 2 0 2 4 
Problems with other 
substances 13 13 1 4/8/1 4/4/5 0 3 7 1 2 0 
Drinks on a specific occasion 9 8 0.9 5/4/0 2/1/6 0 1 7 0 0 1 
Number of drinks in other 
period 8 6 0.8 8/0/0 6/0/2 1 2 1 0 3 1 
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Number of drinks consumed 
in two weeks 6 4 0.7 4/2/0 0/2/4 0 0 4 0 2 0 
Other consumption measure** 5 5 1 1/3/1 0/4/1 0 0 1 2 1 1 
Abuse symptomatology 4 4 1 2/2/0 1/1/2 2 0 0 0 1 1 
Drinking game participation 4 2 0.5 0/4/0 0/0/4 0 0 4 0 0 0 
Preloading alcohol 2 2 1 2/0/0 2/0/0 0 0 1 1 0 0 
Totals 1456 744    176 166 546 219 179 170 
* Ratio of variability is the calculation of the number of variables by the approximate number of ways measured; a higher number suggests greater 
variability. ** Includes the following measures (times measured) drinking non-beverage alcohol (1), average time spent drinking (1), substance 
use successfully verified by a significant other (1), drinking the number of drinks planned to consume that night/meeting personal drinking goal 
(1), whether the participant thought their drinking decreased, increased or stayed the same (1). *** Refers to the number of times an outcome 
appeared in an effectiveness or efficacy trial, or a trial not specified as either. **** Refers to the number of times that an outcome appeared as 
first, second, or not specified as either  
  
Shorter 31 
Table 3: Frequency and variability in reporting of non-consumption variables overall and by population 
Domain and Outcome 
N times 
measured 
N ways 
measured 
Ratio of 
variability* 
Trial type** 
Efficacy/ 
Effectiveness/ 
Not specified 
Outcome 
type*** 
Primary/ 
Secondary/ 
Not specified 
Primary 
care 
N=50 
Emergency 
Department 
N=47 
University/ 
College 
N=132 
General 
population 
N=63 
Other 
healthcare 
N=55 
Other 
N=57 
Biomarkers 
Gamma-glutamyltransferase 10 7 0.7 9/1/0 3/4/3 5     1 
Carbohydrate-deficient transferrin 7 4 0.6 4/3/0 3/4/0 4    1 2 
Mean corpuscular volume 6 4 0.7 5/1/0 2/3/1 3    1 4 
Alanine aminotransferase 4 3 0.8 3/1/0 2/2/0 3     1 
Aspartate aminotransferase 4 3 0.8 3/1/0 2/0/2 3    1 2 
Ethyl Glucuronide/ethyl sulfate 1 1 1 0/1/0 0/1/0      1 
Totals 32 22 0.7   18    3 11 
Economic factors/social impacts 
Driving related offences 60 36 0.6 17/41/2 17/36/7 22 29 3   6 
Hospitalizations 36 11 0.3 26/9/1 5/29/2 17 8  2 4 5 
Use of/seeking alcohol treatment 35 18 0.5 24/9/2 5/25/5 1 15 1 5 4 9 
Other criminal justice use 35 26 0.7 17/18/0 10/19/6 17 6 1  1 10 
Emergency healthcare use 30 8 0.3 18/11/1 7/21/2 12 10  1 2 5 
General or other healthcare use 29 23 0.8 23/5/1 2/23/4 16 2 1 1 4 5 
Intervention cost provider 28 5 0.2 28/0/0 0/28/0 1   1 21 5 
GP/primary care use 24 13 0.5 23/1/0 0/24/0 9 9  3  3 
Alcohol related injuries 18 10 0.6 11/6/1 2/6/10 2 9   1 6 
Outpatient healthcare 14 8 0.6 12/2/0 0/12/2 6 3  1  4 
Social care use 13 10 0.8 13/0/0 1/13/0 9 3   1  
Over the counter/prescribed medication use 11 5 0.5 10/1/0 1/8/2 8   2 1  
Alcohol related offences 11 8 0.7 1/10/0 6/3/2 8  3    
Use of self-help for alcohol 9 8 0.9 6/2/1 0/7/2 1 1 2 3 1 1 
Quality adjusted life years 9 1 0.1 9/0/0 0/9/0 6    1 2 
Other service use 7 7 1 7/0/0 0/7/0 1 4    2 
Intervention cost client 6 5 0.8 6/0/0 0/6/0 2     4 
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Injuries (general) 4 3 0.8 2/2/0 1/2/1 2 2     
Incremental cost-effectiveness ratio 3 1 0.3 3/0/0 0/3/0 2 1     
Intervention cost overall/not specified 3 2 0.7 3/0/0 0/3/0 3      
Other health economic measures 3 3 1 0/2/1 0/1/2   3    
Productivity losses 2 1 0.5 2/0/0 0/2/0 2      
Societal perspectives 2 1 0.5 2/0/0 0/2/0 2      
Substance free reinforcement 2 1 0.5 0/2/0 0/2/0   2    
Totals 401 220 0.5   149 102 23 19 41 67 
Health 
Alcohol-exposed pregnancy factors 31 16 0.5 12/19/0 14/13/4   4 7 18 2 
Psychological health 26 15 0.6 20/4/2 0/23/3 7 3 1 2 6 7 
Sexual violence or coercion 25 21 0.8 17/8/0 4/16/5 2 4 5  6 8 
Severity of depression symptoms 24 13 0.5 13/10/1 6/17/1 4  4 7 4 5 
Physical health 13 6 0.5 13/0/0 0/11/2 7 2  1 1 2 
General health 10 9 0.9 9/1/0 1/5/4 3  1 2 3 1 
Cardiac outcomes 8 2 0.3 8/0/0 0/8/0 6     2 
Other health factors 7 7 1 7/0/0 0/5/2 2 2   3  
Severity of anxiety symptoms 6 6 1 2/4/0 1/5/0   1 2 2 1 
Severity of PTSD symptoms 6 4 0.7 3/3/0 1/5/0   1   5 
Weight/obesity 6 4 0.7 6/0/0 0/6/0 2   4   
Sleep disturbance 6 6 1 6/0/0 0/6/0   6    
Mortality/Death 5 5 1 0/5/0 0/0/5    5   
Suicidality 3 2 0.7 2/0/1 0/3/0 2 1     
Totals 176 116 0.7   35 12 23 30 43 33 
Intervention factors 
Intervention satisfaction 73 54 0.7 29/27/17 1/47/25 3 2 31 26 6 5 
Intervention delivered/used as expected 15 13 0.9 12/3/0 1/9/5  4 4 6 1  
Perceived change in alcohol use 9 9 1.0 3/6/0 0/6/3   3 5  1 
Other intervention factors 2 2 1.0 1/1/0 0/2/0    2   
Totals 99 78 0.8   3 6 38 39 7 6 
Psychological/behavioral factors 
Readiness to change 80 50 0.6 60/17/3 4/49/27 4 14 18 17 12 15 
Shorter 33 
Risky behaviors 49 43 0.9 36/13/0 18/22/9 9 3 6  27 4 
Drinking refusal self-efficacy 43 31 0.7 32/8/3 1/25/17 1 2 8 17 2 13 
Alcohol outcome expectancies 42 42 1 34/8/0 2/28/12  2 11 15 2 12 
Perception of others’ drinking 40 39 1 4/36/0 1/10/29   37 1  2 
Protective behavioral strategy use 17 15 0.9 2/15/0 9/4/4   17    
Anger or aggression 14 14 1 13/1/0 1/1/12 1     13 
Other psychological factors 14 13 0.9 9/5/0 0/6/8 1     13 
Sexual factors 11 8 0.7 10/1/0 2/6/3 3    7 1 
Knowledge of alcohol 10 10 1 9/1/0 1/9/0    8 1 1 
Negative/positive views of alcohol 9 8 0.9 9/0/0 0/6/3  1 2 6   
Alcohol demand curve measures 7 6 0.9 0/7/0 0/3/4   7    
Others’ concern about drinking 7 4 0.6 5/1/1 0/4/3 1  2 1 1 2 
Drinking to cope 6 6 1 4/1/1 1/1/4   4  1 1 
Alcohol-induced memory loss 5 4 0.8 4/0/1 0/3/2   1 1 1 2 
Readiness to receive help 5 5 1 4/1/0 1/2/2  1 1 1 2  
Guilt after drinking 4 3 0.8 3/0/1 0/2/2   1  1 2 
Drinking in the morning 3 2 0.7 2/0/1 0/2/1     1 2 
Impulsivity 2 2 1 1/1/0 0/1/1   1   1 
Goals and goal striving 2 2 1 1/0/1 0/1/1   1 1   
Totals 363 301 0.8   20 23 110 68 58 84 
Life impact 
Role functioning/relationship factors 
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14 
 
 
15 
Quality of life 48 27 0.6 44/1/3 1/44/3 9 5  22 3 9 
Totals 114 71 0.6   13 17 16 27 17 24 
* Ratio of variability is the calculation of the number of variables by the approximate number of ways measured; a higher number suggests greater 
variability. ** Refers to the number of times an outcome appeared in an effectiveness or efficacy trial, or a trial not specified as either. *** Refers 
to the number of times that an outcome appeared as first, second, or not specified as either. 
 
 
 
